Brii Bio reports end-of-treatment results for ENRICH and ENHANCE studiesWorldPharmaceuticals·Jul 6 at 05:35 AM02137+1.08%
Brii Bio Announces Topline End-of-Treatment Data from Phase 2b ENRICH and ENHANCE Studies for the Treatment of Chronic Hepatitis BPR Newswire·Jul 2 at 07:00 PM02137+1.08%VIR+3.01%
Brii Biosciences Posts Promising Phase 2b Hepatitis B Data but Elebsiran Future Clouded by ArbitrationTip Ranks·Jul 2 at 06:07 PM02137+1.08%
Brii Biosciences says arbitration with Vir clouds future of elebsiran programPUBT·Jul 2 at 05:56 PM02137+1.08%VIR+3.01%
Brii Biosciences Launches HK$60 Million Share Buy-back to Signal Confidence and Unlock ValueTip Ranks·Jun 17 at 09:09 AM02137+1.08%
Brii Biosciences and OpenBench collaborate for tech platform. Durham, Beijing, and San Francisco, Dec. 11, 2025.Unusual Whales·Dec 11, 2025 at 06:32 AM02137+1.08%
07:30 ET Brii Biosciences and OpenBench Announce AI-Driven Collaboration for Proprietary Technology Platformprnewswire·Dec 11, 2025 at 06:31 AM02137+1.08%
BRII Biosciences published research data on the therapeutic vaccine BRII-179 for the combination therapy of hepatitis BAASTOCKS·Nov 10, 2025 at 07:21 PM02137+1.08%
